HER2-negative breast cancer patients who have recently completed treatment and now have no evidence of the disease may be eligible to participate in a late-stage clinical trial at the Lester and Sue Smith Breast Center at Baylor College of Medicine that will evaluate the effectiveness of an experimental vaccine to prevent the recurrence of the disease.
Eligibility requirements include:
- Women, 18 years of age and older
- Breast cancer completely excised or completely removed
- Node-positive disease
- HER2 negative
- Completed chemotherapy and/or radiation within two months of enrollment
- Bilateral breast malignancy or suspicious mass in opposite breast
- History of prior breast cancer, ductal carcinoma in situ
- Prior trastuzumab (Herceptin®) therapy
- Cardiac disease
- Autoimmune diseases or immune deficiency disease
- Patients on chronic steroid therapy, other immunosuppressive therapy
For more detailed information about enrolling in the study at BCM, contact Ashley Whittington at 713-798-8874 or firstname.lastname@example.org. For additional information and to inquire about enrolling at other centers, call 1-855-855-GALE, ext. 112 or e-mail email@example.com.
Patients who are enrolled in the study can expect to make 18 study visits over three years as well as a follow-up period of up to 10 years from the time of enrollment.
Manufactured by Galena Biopharma, the vaccine is a peptide vaccine being developed for use after completion of standard-of-care therapy to potentially prevent recurrence of breast cancer.